Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for

Melissa A Rolfes1, Joshua Rhein2, Charlotte Schutz3

  • 1Department of Medicine , Medical School, University of Minnesota.

Insights

Persistent fungal presence in cerebrospinal fluid (CSF) after initial treatment for human immunodeficiency virus (HIV)-associated cryptococcal meningitis did not increase mortality risks in a recent African study. Enhanced antifungal therapy and timely antiretroviral treatment mitigated negative outcomes.

Area of Science:

  • Infectious Diseases
  • Mycology
  • Immunology

Background:

  • Amphotericin-based combination therapy is crucial for reducing mortality in HIV-associated cryptococcal meningitis.
  • A significant proportion (40%-50%) of patients exhibit positive cerebrospinal fluid (CSF) fungal cultures after 2 weeks of amphotericin induction.
  • Historically, residual CSF positivity has been linked to adverse clinical outcomes.

Purpose of the Study:

  • To investigate the association between persistent CSF fungemia and clinical outcomes in a contemporary African cohort with HIV-associated cryptococcal meningitis.
  • To evaluate the impact of residual fungal culture positivity on mortality, immune reconstitution inflammatory syndrome (IRIS), and relapse.

Main Methods:

  • A cohort of HIV-infected individuals with cryptococcal meningitis in Uganda and South Africa received amphotericin and fluconazole induction therapy.
  • Patients were subsequently treated with enhanced consolidation therapy (fluconazole) and randomized to receive antiretroviral therapy (ART) at 1-2 weeks or 5 weeks post-diagnosis.
  • Outcomes including mortality, IRIS, and relapse were compared between patients with sterile versus non-sterile CSF cultures at 2 weeks using Cox regression.

Main Results:

  • Of 132 survivors at 2 weeks, 57% had sterile CSF; 40-day mortality was 17% (23/132) and 6-month mortality was 30% (40/132).
  • Residual CSF culture positivity at 2 weeks was not significantly associated with 6-month mortality (adjusted HR, 1.2; 95% CI, 0.6-2.3; P = .28).
  • Incidence of IRIS or culture-positive relapse was also not significantly related to 2-week CSF culture status.

Conclusions:

  • In patients receiving enhanced consolidation antifungal therapy and ART, residual cryptococcal positivity in CSF was not associated with adverse clinical outcomes.
  • This suggests that modern treatment strategies may overcome the negative prognostic implications of persistent fungemia in HIV-associated cryptococcal meningitis.